Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
10:10am, Tuesday, 22'nd Apr 2025
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
10:25am, Monday, 21'st Apr 2025
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
11:31am, Friday, 18'th Apr 2025
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
11:15am, Friday, 18'th Apr 2025
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
12:50pm, Wednesday, 16'th Apr 2025
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
01:00am, Tuesday, 15'th Apr 2025
Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig
Why You Shouldn't Bet Against Sanofi (SNY) Stock
10:10am, Friday, 11'th Apr 2025
Sanofi (SNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
01:11pm, Tuesday, 08'th Apr 2025
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
12:30pm, Thursday, 03'rd Apr 2025
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
12:08pm, Thursday, 03'rd Apr 2025
The U.S. Food and Drug Administration (FDA) on Thursday granted orphan drug designation to Sanofi SA‘s SNY rilzabrutinib.
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
01:00am, Thursday, 03'rd Apr 2025
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
07:00am, Wednesday, 02'nd Apr 2025
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
10:45am, Tuesday, 01'st Apr 2025
The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without inhibitors.
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
04:07pm, Friday, 28'th Mar 2025
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent prot
US FDA approves Sanofi's bleeding disorder therapy
02:27pm, Friday, 28'th Mar 2025
The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents b
